Editorial: Psoriasis, inflammation, and vascular risk: A problem more than skin deep?

European Heart Journal

Volumn 31, Issue 8, 2010, Pages 902-904

  Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; METHOTREXATE; PLACEBO; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL ADHESION; CELL MIGRATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EDITORIAL; ENDOTHELIUM CELL; ENTERITIS; FOLLOW UP; GROUPS BY AGE; HEART DEATH; HEART INFARCTION; HELPER CELL; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHESIS; INCIDENCE; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; ISCHEMIA; LIPID BLOOD LEVEL; LIVER CELL; LOW DRUG DOSE; MONOCYTE; PERIODONTAL DISEASE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK REDUCTION; SMOKING; SMOOTH MUSCLE FIBER; STROKE; CARDIOVASCULAR DISEASE; HUMAN; MORTALITY; NOTE; RISK FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; PSORIASIS; RISK FACTORS;

EID: 77951117952     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq042     Document Type: Editorial

References (15)

1. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophy-siology to practice. J Am Coll Cardiol 2009;54:2129-2138.
2. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-424.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
4. Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, Canning C, Schneeweiss S. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rhuem Dis 2006;65:1608-1612.
5. Genco R, Offenbacher S, Beck J. Periodontal disease and cardiovascular disease: epidemiology and possible mechanisms. J Am Dent Assoc 2002;133:12s-22s.
6. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myo-cardial infarction in patients with psoriasis. JAMA 2006;296:1735-1741. (Pubitemid 44547793)
7. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000-1006. First published on 27 December 2009. doi:10.1093/eurheartj/ ehp567.
8. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009;151:483-495.
9. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gottto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
10. Arnaud C, Braunersreuther V, Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med 2005;15: 202-206.
11. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28.
12. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gottto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ on behalf of the JUPITER Trial Study Group. Reduction in C-reactive protein and LDL-cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373:1175-1182.
13. Crossman DC, Morton AC, Gunn JP, Greenwood JP, Hall AS, Fox KA, Lucking AJ, Flather MD, Lees B, Foley CE. Investigation of the effect of interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coron-ary syndrokes (The MRC-ILA-HEART Study). Trials 2008;9:8 (http://www. trialsjournal.com/content/9/1/8).
14. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009;7 (Suppl 1):332-339.
15. Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, Ostol AJK, Edwards CJ. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systemic literature review. Rheumatology 2010;49: 295-307.